Lyesfal

General characteristics. Structure:

Active ingredient: 1 ml of solution contains phosphatidylsincaline from soybeans 50 mg;

excipients: benzyl alcohol, acid dezoksikholiyevy, sodium chloride, sodium hydroxide, Riboflavinum (Е 101), water for injections.

Pharmacological properties:

Pharmacodynamics. The phospholipids which are contained in drug on the chemical structure are similar to endogenous phospholipids, but much more exceed them on the content of polyunsaturated (essential) fatty acids. These high-energy molecules are built in preferential structures of cellular membranes and facilitate recovery of the damaged liver tissues. Phospholipids influence the broken lipidic metabolism by regulation of metabolism of lipoproteins, as a result of it neutral fats and cholesterol turn into the forms suitable for transportation, especially thanks to increase in ability of lipoproteins of the high density (LPVP) to attach cholesterol, and are intended for further oxidation. During removal of phospholipids through biliary tract the litogenny index decreases and there is a bile stabilization.

Pharmacokinetics. The elimination half-life for a choline component makes 66 hours, for saturated fatty acids – 32 hours.

In kinetics researches in a human body less than 5% of each of the entered isotopes 3H and 14C were removed with excrements.

Pharmaceutical characteristics

Main physical and chemical properties: transparent yellow solution.
Incompatibility

 

It is impossible to mix in one syringe with other medicines.

Drug is not compatible to electrolytic solutions.

Indications to use:

Fatty degeneration of a liver, acute and chronic hepatitises, cirrhosis, before - and postoperative treatment of the patient at surgical intervention on a liver and biliary tract, toxic damages of a liver, toxicosis of pregnant women, psoriasis, a radiation syndrome.

Route of administration and doses:

It is necessary to apply only transparent solution.

The drug is administered intravenously slowly. It is impossible to administer the drug intramusculary because of possible emergence of local reaction.

To adults and children 12 years are more senior appoint intravenously slowly 5-10 ml a day, and in hard cases – from 10 to 20 ml a day. For once it is allowed to enter 10 ml of drug. For cultivation of drug it is recommended to use own blood of the patient in the ratio 1:1. The course of treatment makes up to 10 days with the subsequent transition to peroral forms of phosphatidylsincaline.

Treatment of psoriasis is begun with reception of peroral forms of phosphatidylsincaline within 2 weeks. After that 10 intravenous injections on 5 ml with PUVA therapy co-administration are recommended. After the termination of a course of injections resume reception of peroral forms of phosphatidylsincaline.

In cases when for cultivation of drug it is impossible to use own blood of the patient, it is necessary to apply solutions, free from electrolytes – 5% or 10% solution of glucose, 5% xylitol solution in the ratio 1:1.

Features of use:

Cautions: solution contains alcohol 5,02 mg/ml.

Only for intravenous use.

Ability to influence speed of response at control of motor transport or work with other mechanisms

 

It is not revealed.

Side effects:

In some cases at use of the raised doses of drug disturbances from digestive tract are possible (diarrhea). In isolated cases there can be a hypersensitivity reaction, rash, an itch.

Interaction with other medicines:

Interaction with other medicines was not studied. Drug is not compatible to electrolytic solutions. Not to administer the drug together with other medicines in one syringe.

Contraindications:

Hypersensitivity to any of drug components.

Overdose:

Messages on overdose were not.

Use during pregnancy or feeding by a breast

Drug is used for treatment of toxicosis of pregnant women.

Drug is not contraindicated to use during feeding by a breast.

It is put 

Drug is appointed for treatment of children 12 years are more senior.

Storage conditions:

Period of validity 2 years. Not to apply after the termination of the period of validity specified on packaging. To store in the place protected from light at a temperature from 2 °C to 8 °C. To store in the place, unavailable to children.

Issue conditions:

According to the recipe

Packaging:

On 5 ml in an ampoule. On 5 or 10 ampoules in a pack.

On 5 ampoules in the blister. On 1 or 2 blisters in a pack.